E-Posters-A Novel Bladder Injection System Used for OnabotulinumtoxnA Treatment of Overactive Bladder (OAB)

A Novel Bladder Injection System Used for OnabotulinumtoxnA Treatment of Overactive Bladder (OAB) - John J. Smith III, MD, MS, FACS

Back to course

Pdf Summary

The study assessed the safety and efficacy of a novel bladder injection system for the treatment of overactive bladder (OAB) using the drug OnabotulinumtoxinA (Botox). The system was designed to reduce post-procedure urinary retention, a common complication. Adult female OAB patients were included in the study and a single-use introducer with an injection needle and sheath was used to inject Botox into the bladder wall. The injection sites were along the lateral wall of the bladder. Pain levels during the procedure were ranked by the patients, and a follow-up call was conducted to assess urinary retention. The study found that all 130 procedures were completed successfully with no adverse events associated with the injection system. Only one out of 130 patients experienced post-procedure urinary retention requiring intermittent catheterization. The novel injection system allowed for easy adherence to the injection protocol, resulting in minimal patient discomfort. These results were consistent with an earlier study, validating the effectiveness of the system in reducing urinary retention. Further investigations are warranted to explore the potential of this novel device and injection protocol.

Keywords

bladder injection system

overactive bladder

OnabotulinumtoxinA

Botox

post-procedure urinary retention

adult female OAB patients

injection needle and sheath

bladder wall

pain levels

adverse events